Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 10/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 10/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 10/20 | 0.39 |
| ▸ | CASP1 | P29466 | 3/20 | 0.38 |
| ▸ | CASP5 | P51878 | 3/20 | 0.38 |
| ▸ | CASP4 | P49662 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16398122 | 0.87 | TACR1 (0.37) | TACR1SLC6A4KCNH2HRH4CNR2 | |
| SCHEMBL16397920 | 0.78 | CHRM3 (0.37) | CASP1CASP5CASP4MAPTHRH4 | |
| SCHEMBL16397831 | 0.76 | TACR1 (0.36) | TACR1SLC6A4KCNH2ALDH1A1 | |
| SCHEMBL19773364 | 0.75 | TACR1 (0.39) | TACR1SLC6A4KCNH2CASP1CASP5 | |
| SCHEMBL16397727 | 0.74 | ALDH1A1 (0.34) | TACR1SLC6A4KCNH2LMNATSHR | |
| SCHEMBL16398389 | 0.72 | HTR2A (0.34) | TACR1SLC6A4KCNH2CNR2LMNA | |
| SCHEMBL16397842 | 0.71 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL16398232 | 0.70 | NPC1 (0.33) | TACR1SLC6A4KCNH2MAPTRAB9A | |
| SCHEMBL16398065 | 0.70 | MEN1 (0.40) | TACR1SLC6A4KCNH2MAPTCYP1A2 | |
| SCHEMBL2179648 | 0.70 | GBA1 (0.43) | CASP1CASP5CASP4MAPTHRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3004079-B1 | PYRIMIDINE COMPOUNDS AND THEIR USE AS GAMMA SECRETASE MODULATORS | ACTURUM REAL ESTATE AB (SE) | 2018-01-17 | — | — | EP | disclosed |
| US-9439904-B2 | Pyrimidine compounds and their use as gamma secretase modulators | Acturum Life Science AB (SE) | 2016-09-13 | — | — | US | disclosed |
| US-9439904-B2 | Pyrimidine compounds and their use as gamma secretase modulators | Acturum Life Science AB (SE) | 2016-09-13 | — | — | US | disclosed |
| US-9439904-B2 | Pyrimidine compounds and their use as gamma secretase modulators | Acturum Life Science AB (SE) | 2016-09-13 | — | — | US | disclosed |
| US-20160129002-A1 | PYRIMIDINE COMPOUNDS AND THEIR USE AS GAMMA SECRETASE MODULATORS | Acturum Life Science AB (SE) | 2016-05-12 | — | — | US | disclosed |
| US-20160129002-A1 | PYRIMIDINE COMPOUNDS AND THEIR USE AS GAMMA SECRETASE MODULATORS | Acturum Life Science AB (SE) | 2016-05-12 | — | — | US | disclosed |
| US-20160129002-A1 | PYRIMIDINE COMPOUNDS AND THEIR USE AS GAMMA SECRETASE MODULATORS | Acturum Life Science AB (SE) | 2016-05-12 | — | — | US | disclosed |
| EP-3004079-A1 | PYRIMIDINE COMPOUNDS AND THEIR USE AS GAMMA SECRETASE MODULATORS | Acturum Life Science AB (SE) | 2016-04-13 | — | — | EP | disclosed |
| WO-2014195323-A1 | PYRIMIDINE COMPOUNDS AND THEIR USE AS GAMMA SECRETASE MODULATORS | Acturum Life Science AB (SE) | 2014-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160129002-A1 | PYRIMIDINE COMPOUNDS AND THEIR USE AS GAMMA SECRETASE MODULATORS | BACE1, BACE2, APP | TACR1 1350/4885SLC6A4 3517/4885KCNH2 4199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.